May 6 |
5 Biotech Stocks Worth Adding to Your Portfolio in 2024
|
May 6 |
BioMarin touts new data on Voxzogo for additional indications
|
May 4 |
New Data for BioMarin's VOXZOGO® (vosoritide) for Multiple Growth-Related Conditions in Children Presented at Pediatric Endocrine Society (PES) Annual Meeting
|
May 3 |
Citi Just Cut Its Price Target on These 3 Stocks
|
Apr 30 |
BioMarin Pharmaceutical Inc. Beat Analyst Estimates: See What The Consensus Is Forecasting For This Year
|
Apr 29 |
BioMarin Pharmaceutical Investors Overfocused on Roctavian, Distracted From Enzyme Replacement Therapies, UBS Says
|
Apr 27 |
4 Dominant Growth Stocks You'll Regret Not Buying in the New Nasdaq Bull Market
|
Apr 27 |
Beyond the Balance Sheet: What SWOT Reveals About Biomarin Pharmaceutical Inc (BMRN)
|
Apr 26 |
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) Q1 2024 Earnings Call Transcript
|
Apr 26 |
BioMarin Pharmaceutical First Quarter 2024 Earnings: EPS Beats Expectations
|